Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




DrStockPick.com Stock Report! 10/12/09, GAS, SOTK, OSK, TDW, DNDN, EMCI

Dr. Stock Pick (October 12th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_______________________________________

Monday October 12, 2009

DrStockPick.com Stock Report!

**************************************************************

Today Central Valley Gas Storage, L.L.C., a subsidiary of Nicor Inc. (NYSE: GAS) of Naperville, Illinois, announced that it will hold a non-binding open season for firm storage services beginning April 1, 2012. The open season will begin on October 12, 2009 and extend through November 12, 2009.

Sono-Tek Corporation (OTC Bulletin Board: SOTK) today announced sales of $1,683,883 for the three months ended August 31, 2009, compared to sales of $1,605,482 for the prior year period, an

...
More »
Tags for this Post:
Australian Department of Defence, Central Valley Gas Storage L.L.C., chief executive officer and head, Dendreon Corporation;, Dr Stock Pick, Eli Lilly & Company, EMC Insurance Group Inc;, energy, firm storage services, food processing equipment, head, head of global product, head of global product strategy and chief marketing officer, Ian Clark, Illinois, industrial coating equipment, Insurance Services Office Inc., Investing Lessons, medical device equipment, Naperville;, Nicor Inc, Oshkosh Corporation;, Pedro Granadillo, Plasan SASA Ltd., Roche Group;, Senior Vice President, senior vice president of global manufacturing and human resources, Sono-Tek Corporation, Stocks to Watch, strategy and chief marketing officer, Tidewater Inc, ultrasonic atomization technology, USD, Verisk Analytics Inc., wasteful conventional spraying systems

Posted in Investing Lessons, Stocks to Watch | No Comments »

Dendreon Awaits Provenge Approval – Analyst Blog

Zacks Market Commentaries (September 28th, 2009) Writes:
Dendreon Corporation (DNDN) is likely to become the first company to receive approval from the US Food and Drug  Administration (FDA) for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results for its key product candidate, Provenge, in April 2009. Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of 2009. We believe that the FDA will approve Provenge in the first half of 2010 based on the positive late-stage study results. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S. We believe Provenge could have blockbuster potential if it is approved by the regulators. Prostate cancer is the most ...
More »

Posted in Investing Lessons, Stocks to Watch | No Comments »

GenVec’s TNFerade Nears NDA Status (NASDAQ:GNVC)

Michael Vlaicu (September 9th, 2009) Writes:

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...
More »
Tags for this Post:
adenovector delivery, adenovector delivery technology, adenovector technology, adenovector vaccine candidate, adenovirus, Agricultural Research Service, Allergy, America, Analyst, and Lead Investment Analyst, antibodies, Antigenics Inc., Apple Inc, Associate Professor, balance disorders, bank of america corp, Barclays, Biotechnology, California, cancer, Cancer Research, Cancers, care for patients with balance disorders, ceo, Chemotherapy, clinical disease, Dendreon Corporation;, director, Douglas J. Swirsky, esophageal cancer, Executive Vice President, Executive Vice President of Research and Development, Fda, fibrosis;, Food Supply, foot-and-mouth disease, founder, Gaithersburg;, gene expression, gene therapy, GenVec Inc., Head And Neck Cancer, hearing loss;, HIV, Infectious Diseases, Laszlo Zsak, lead therapeutic product candidate, locally advanced pancreatic cancer, Major, Malaria, manager, Marvin Grubman, Maryland, meat products, Michael Vlaicu;, multi-purpose products, National Institute of Allergy, National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Naval Medical Research Center, necrosis, Oncologix Inc., Pancreatic Cancer, parasitic disease, Patrick Swazy, Paul H. Fischer, Pfizer Inc, Ph.D., Pharmaceutical, Plum Island Animal Disease Center, president and chief executive officer, Professor of Human Oncology, Q1, radiation, rectal cancer, Researchers of the Livestock Sciences, Reuters, Royce Micro, SAIC-Frederick Inc., San Francisco, second-generation vaccine candidate, Spartan Micro, stage biopharmaceutical;, Steve Jobs, Stocks to Watch, targeted radiation therapy, therapy for locally advanced pancreatic cancer, TherAtoh, TNFerade;, TNFerade™;, transcriptional start site, treatment of inoperable, treatment of locally advanced pancreatic cancer;, treatment of pancreatic cancer, treatment of various cancers;, tumor, tumors, U.S. Department of Agriculture, U.S. Food and Drug Administration, United Kingdom, United States, University of California at San Francisco, University of California Irvine Comprehensive Digestive Disease Center, University of Denver, University Of Wisconsin, USD, USDA, vaccine candidate, Vaccine Research Center, Vaccine Research Center/National Institute, Vaccines, Vice President and Chief Financial Officer, Vice President of Research and Development, Wisconsin, Yahoo, yale, Yale University School of Medicine

Posted in Stocks to Watch | No Comments »

PennyOmega.com Stock Report! 8/11/09, DNDN, XWES, TLF, CBRX, ELC, AEY

Penny Omega (August 11th, 2009) Writes:

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

signup3m

 

Tuesday August 11, 2009

PennyOmega.com Stock Report!

**************************************************************

Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended June 30, 2009. Revenue for the second quarter of 2009 was $25,000 compared to $26,000 for the quarter ended June 30, 2008. Revenue for the six months ended June 30, 2009 was $55,000 compared to $57,000 for the six months ended June 30, 2008.

World Energy Solutions, Inc. (NASDAQ: XWES), an operator of online exchanges for energy and green commodities, today announced a channel partnership with Commercial Utility Consultants (CUC). The companies have teamed to help Pennsylvania businesses take advantage of newly opened electricity markets created by the impending

...
More »

Posted in Market Commentary, Stocks to Watch | No Comments »

Dendreon Gets Positive IMPACT – Analyst Blog

Zacks Market Commentaries (April 14th, 2009) Writes:
Positive IMPACT trial results will likely lead to Provenge approval by the FDA in 1H10This morning, Dendreon Corporation (DNDN) announced results of the long-awaited pivotal phase III IMPACT study of Provenge in men with advanced prostate cancer. In the news release and the conference call, management disclosed that the phase III study met its primary endpoint of improving overall survival compared to a placebo. The magnitude of the survival difference observed in the intent to treat population resulted in the study successfully achieving the pre-specified level of statistical significance defined by the study's design. The safety profile of Provenge appeared to be consistent with prior trials.As a reminder, Dendreon's lead drug candidate Provenge is under phase III IMPACT confirmatory study for prostate cancer under a special protocol assessment (SPA) with the FDA. Provenge is a therapeutic vaccine. Previous two phase III studies ...
More »

Posted in Market Commentary, Stocks to Watch | No Comments »

Federally Approved Stem Cell Therapy: Time to Look at Stem Cell Stocks

Fred Fuld (February 4th, 2009) Writes:

a onblur=”try {parent.deselectBloggerImageGracefully();} catch(e) {}” href=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s1600-h/stem_cells.jpg”img style=”float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px; height: 169px;” src=”http://2.bp.blogspot.com/_T9VXVyuEITg/SYksOvCIT5I/AAAAAAAAAoM/DrrO_JiQPJ8/s200/stem_cells.jpg” border=”0″ alt=”"id=”BLOGGER_PHOTO_ID_5298815068233289618″ //abr /Since President Obama has decided to repeal the limitations imposed on embryonic stem cell research, and since the first federally approved human study utilizing embryonic stem cell therapy is now taking place, investors are now looking at opportunities in stem cell stocks. Extensive research is being done to utilize stem cells for a href=”http://stockerblog.blogspot.com/2008/05/gene-therapy-stocks.html” target-”_blank”gene therapy/a and the treatment of multiple sclerosis, Parkinson’s disease, heart disease, diabetes, arthritis, and many other medical conditions. br /br /A source of stem cells is a href=”http://cordbloodstocks.com/” target-”_blank”cord blood/a, the blood from an umbilical cord. The saving and storing of cord blood has become a fast growing business. For example, Richard Branson, founder and head of Virgin Records and Virgin Atlantic Airways, set up a cord blood bank. Even a href=”http://stockerblog.blogspot.com/2007/10/stem-cell-bonds-issued-by-california.html” target-”_blank”Stem Cell …

More »

Tags for this Post:
Abbott Laboratories, Alexion Pharmaceuticals;, antibodies, ARIAD Pharmaceuticals;, Arthritis, biologic therapeutic products;, biomaterials, Biotechnology, California, cancer, cancer products, Celera Group;, cell enrichment device;, cell products, cell signaling;, cell technology, cell therapy, Connecticut, Cord Blood Bank, Current Market News, Cystic Fibrosis, Cytori Therapeutics Inc.;, Dendreon Corporation;, Diabetes, Diagnostic Products, endometrial cancer;, erythema nodosum;, gene analysis;, gene cloning;, gene therapy, Genentech, General Electric, genomics, Heart Disease, heart failure, hepatitis C, HIV, human neural stem cell ;, human neural stem cell technology;, immune diseases;, Integra Lifesciences Holdings, Invitrogen Corporation, leprosy;, liver diseases;, Massachusetts, Multiple Sclerosis, National Institute of Health, Neuralstem Inc.;, New Jersey, obama, Osiris Therapeutics Inc.;, Parkinson's disease, Peg, Pharmaceutical, Prince Edward Island, Prostate Cancer, proteomics, regenerative medicine medical ;, regenerative medicine medical technologies;, Richard Branson, sarcomas;, Stem Cells, StemCells Inc., Stocks to Watch, treatment of hematologic and cardiovascular disorders;, treatment of multiple sclerosis;, treatment of various diseases;, tumors, USD, Virgin Atlantic Airways

Posted in Current Market News, Stocks to Watch | No Comments »


Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.